BAVARIAN NORDIC ADR Aktie

 

COPENHAGEN, Denmark, March 30, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on...

COPENHAGEN, Denmark, March 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, March 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523....

The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- The post Bavarian Nordic and SII sign agreement for chikungunya vaccine production appeared first on Pharmaceutical Business review....

COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026....

COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, 2026. The report is attached and available on www.bavarian-nordic.com....

COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited....

Bavarian Nordic A/S's Chief Executive officer Paul Chaplin will step down, marking the second major leadership shake-up at the vaccine maker since shareholders torpedoed a takeover bid last year....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO....

COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company's mpox and smallpox vaccine, MVA-BN®....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Bavarian Nordic announces preliminary, unaudited financial results for 2025 and provides financial guidance for 2026....

COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure....

COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

Bavarian Nordic has signed a distribution agreement with Eurofarma for its chikungunya vaccine in Brazil with potential to expand to rest of Latin America...

COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....